Metabolic profiling of a transgenic Caenorhabditis elegans Alzheimer model

Roel Van Assche; Liesbet Temmerman; Daniel A. Dias; Berin Boughton; Kurt Boonen; Bart P. Braeckman; Liliane Schoofs; Ute Roessner

doi:10.1007/s11306-014-0711-5

Metabolic profiling of a transgenic Caenorhabditis elegans Alzheimer model

Roel Van Assche^*, Liesbet Temmerman, Daniel A. Dias, Berin Boughton, Kurt Boonen, Bart P. Braeckman, Liliane Schoofs, Ute Roessner

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Despite decades of research, no early-onset biomarkers are currently available for Alzheimer’s disease, a cureless neurodegenerative disease afflicting millions worldwide. In this study, transgenic Caenorhabditis elegans were used to investigate changes in the metabolome after induced expression of amyloid-β. GC- and LC–MS-based platforms determined a total of 157 differential features. Some of these were identified using in-house (GC–MS) or public libraries (LC–MS), revealing changes in allantoin, cystathionine and tyrosine levels. Since C. elegans is far better suited to metabolomics studies than most other model systems, the accordance of these findings with vertebrate literature is promising and argues for further use of C. elegans as a model of human pathology in the study of AD.

Original language	English
Pages (from-to)	477-486
Number of pages	10
Journal	Metabolomics
Volume	11
Issue number	2
DOIs	https://doi.org/10.1007/s11306-014-0711-5
Publication status	Published - 2015
Externally published	Yes

Access to Document

10.1007/s11306-014-0711-5

Cite this

@article{bbe76103d4314256a3529e4946196434,

title = "Metabolic profiling of a transgenic Caenorhabditis elegans Alzheimer model",

abstract = "Despite decades of research, no early-onset biomarkers are currently available for Alzheimer{\textquoteright}s disease, a cureless neurodegenerative disease afflicting millions worldwide. In this study, transgenic Caenorhabditis elegans were used to investigate changes in the metabolome after induced expression of amyloid-β. GC- and LC–MS-based platforms determined a total of 157 differential features. Some of these were identified using in-house (GC–MS) or public libraries (LC–MS), revealing changes in allantoin, cystathionine and tyrosine levels. Since C. elegans is far better suited to metabolomics studies than most other model systems, the accordance of these findings with vertebrate literature is promising and argues for further use of C. elegans as a model of human pathology in the study of AD.",

keywords = "Alzheimer{\textquoteright}s disease, Amyloid-β, Caenorhabditis elegans, Metabolic profiling, Metabolomics",

author = "{Van Assche}, Roel and Liesbet Temmerman and Dias, {Daniel A.} and Berin Boughton and Kurt Boonen and Braeckman, {Bart P.} and Liliane Schoofs and Ute Roessner",

note = "Publisher Copyright: {\textcopyright} 2014, The Author(s).",

year = "2015",

doi = "10.1007/s11306-014-0711-5",

language = "English",

volume = "11",

pages = "477--486",

journal = "Metabolomics",

issn = "1573-3882",

publisher = "Springer",

number = "2",

}

TY - JOUR

T1 - Metabolic profiling of a transgenic Caenorhabditis elegans Alzheimer model

AU - Van Assche, Roel

AU - Temmerman, Liesbet

AU - Dias, Daniel A.

AU - Boughton, Berin

AU - Boonen, Kurt

AU - Braeckman, Bart P.

AU - Schoofs, Liliane

AU - Roessner, Ute

PY - 2015

Y1 - 2015

N2 - Despite decades of research, no early-onset biomarkers are currently available for Alzheimer’s disease, a cureless neurodegenerative disease afflicting millions worldwide. In this study, transgenic Caenorhabditis elegans were used to investigate changes in the metabolome after induced expression of amyloid-β. GC- and LC–MS-based platforms determined a total of 157 differential features. Some of these were identified using in-house (GC–MS) or public libraries (LC–MS), revealing changes in allantoin, cystathionine and tyrosine levels. Since C. elegans is far better suited to metabolomics studies than most other model systems, the accordance of these findings with vertebrate literature is promising and argues for further use of C. elegans as a model of human pathology in the study of AD.

AB - Despite decades of research, no early-onset biomarkers are currently available for Alzheimer’s disease, a cureless neurodegenerative disease afflicting millions worldwide. In this study, transgenic Caenorhabditis elegans were used to investigate changes in the metabolome after induced expression of amyloid-β. GC- and LC–MS-based platforms determined a total of 157 differential features. Some of these were identified using in-house (GC–MS) or public libraries (LC–MS), revealing changes in allantoin, cystathionine and tyrosine levels. Since C. elegans is far better suited to metabolomics studies than most other model systems, the accordance of these findings with vertebrate literature is promising and argues for further use of C. elegans as a model of human pathology in the study of AD.

KW - Alzheimer’s disease

KW - Amyloid-β

KW - Caenorhabditis elegans

KW - Metabolic profiling

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=84944279449&partnerID=8YFLogxK

U2 - 10.1007/s11306-014-0711-5

DO - 10.1007/s11306-014-0711-5

M3 - Article

SN - 1573-3882

VL - 11

SP - 477

EP - 486

JO - Metabolomics

JF - Metabolomics

IS - 2

ER -

Metabolic profiling of a transgenic Caenorhabditis elegans Alzheimer model

Abstract

Access to Document

Other files and links

Fingerprint

Cite this